363 related articles for article (PubMed ID: 24833665)
1. A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma.
Nadal E; Zhong J; Lin J; Reddy RM; Ramnath N; Orringer MB; Chang AC; Beer DG; Chen G
Clin Cancer Res; 2014 Jun; 20(12):3107-17. PubMed ID: 24833665
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer.
Lu Y; Govindan R; Wang L; Liu PY; Goodgame B; Wen W; Sezhiyan A; Pfeifer J; Li YF; Hua X; Wang Y; Yang P; You M
Carcinogenesis; 2012 May; 33(5):1046-54. PubMed ID: 22331473
[TBL] [Abstract][Full Text] [Related]
3. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer.
Duncavage E; Goodgame B; Sezhiyan A; Govindan R; Pfeifer J
J Thorac Oncol; 2010 Nov; 5(11):1755-63. PubMed ID: 20975375
[TBL] [Abstract][Full Text] [Related]
4. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
5. Association of miR-193b down-regulation and miR-196a up-regulation with clinicopathological features and prognosis in gastric cancer.
Mu YP; Tang S; Sun WJ; Gao WM; Wang M; Su XL
Asian Pac J Cancer Prev; 2014; 15(20):8893-900. PubMed ID: 25374225
[TBL] [Abstract][Full Text] [Related]
6. Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients.
González-Vallinas M; Rodríguez-Paredes M; Albrecht M; Sticht C; Stichel D; Gutekunst J; Pitea A; Sass S; Sánchez-Rivera FJ; Lorenzo-Bermejo J; Schmitt J; De La Torre C; Warth A; Theis FJ; Müller NS; Gretz N; Muley T; Meister M; Tschaharganeh DF; Schirmacher P; Matthäus F; Breuhahn K
Mol Cancer Res; 2018 Mar; 16(3):390-402. PubMed ID: 29330288
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value.
Namkung J; Kwon W; Choi Y; Yi SG; Han S; Kang MJ; Kim SW; Park T; Jang JY
J Gastroenterol Hepatol; 2016 Jun; 31(6):1160-7. PubMed ID: 26644397
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of microRNA expression profiling in non small cell lung cancer.
Markou A; Sourvinou I; Vorkas PA; Yousef GM; Lianidou E
Lung Cancer; 2013 Sep; 81(3):388-396. PubMed ID: 23756108
[TBL] [Abstract][Full Text] [Related]
9. Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma.
Hamamoto J; Soejima K; Yoda S; Naoki K; Nakayama S; Satomi R; Terai H; Ikemura S; Sato T; Yasuda H; Hayashi Y; Sakamoto M; Takebayashi T; Betsuyaku T
Mol Med Rep; 2013 Aug; 8(2):456-62. PubMed ID: 23759980
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
[TBL] [Abstract][Full Text] [Related]
11. An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.
Hill KE; Kelly AD; Kuijjer ML; Barry W; Rattani A; Garbutt CC; Kissick H; Janeway K; Perez-Atayde A; Goldsmith J; Gebhardt MC; Arredouani MS; Cote G; Hornicek F; Choy E; Duan Z; Quackenbush J; Haibe-Kains B; Spentzos D
J Hematol Oncol; 2017 May; 10(1):107. PubMed ID: 28506242
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.
Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN
Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871
[TBL] [Abstract][Full Text] [Related]
13. MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.
Sondermann A; Andreghetto FM; Moulatlet AC; da Silva Victor E; de Castro MG; Nunes FD; Brandão LG; Severino P
Clin Exp Metastasis; 2015 Aug; 32(6):521-30. PubMed ID: 26007293
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
15. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
[TBL] [Abstract][Full Text] [Related]
16. Expression level of miRNAs on chromosome 14q32.31 region correlates with tumor aggressiveness and survival of glioblastoma patients.
Shahar T; Granit A; Zrihan D; Canello T; Charbit H; Einstein O; Rozovski U; Elgavish S; Ram Z; Siegal T; Lavon I
J Neurooncol; 2016 Dec; 130(3):413-422. PubMed ID: 27573219
[TBL] [Abstract][Full Text] [Related]
17. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma.
Liu N; Cui RX; Sun Y; Guo R; Mao YP; Tang LL; Jiang W; Liu X; Cheng YK; He QM; Cho WC; Liu LZ; Li L; Ma J
Int J Cancer; 2014 Mar; 134(6):1359-68. PubMed ID: 23999999
[TBL] [Abstract][Full Text] [Related]
18. Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma.
Kerimis D; Kontos CK; Christodoulou S; Papadopoulos IN; Scorilas A
Clin Biochem; 2017 Apr; 50(6):285-292. PubMed ID: 27939727
[TBL] [Abstract][Full Text] [Related]
19. Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor.
Zehavi L; Avraham R; Barzilai A; Bar-Ilan D; Navon R; Sidi Y; Avni D; Leibowitz-Amit R
Mol Cancer; 2012 Jul; 11():44. PubMed ID: 22747855
[TBL] [Abstract][Full Text] [Related]
20. Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression.
Li CY; Liang GY; Yao WZ; Sui J; Shen X; Zhang YQ; Peng H; Hong WW; Ye YC; Zhang ZY; Zhang WH; Yin LH; Pu YP
Clin Transl Oncol; 2017 Feb; 19(2):162-172. PubMed ID: 27173517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
